INSIGHTS ON DRUG DEVELOPMENT

• Column Selection For RPLC-UV Impurity Analysis

  Explore the performance of four column chemistries for RPLC-UV impurity analysis of liraglutide and semaglutide, which offers practical guidance for method development in peptide-based therapeutics.

• Why CDMO Performance Drops Exactly When It Matters Most

  Programs often stall moving to GMP due to fragmented workflows and knowledge gaps. Aligning teams and integrating development with execution, via continuous data, sustains momentum and reduces risk.

• Improved Cell Viability For Multi-Day Cell-Based Assays

  Ensure consistent cell health and assay reliability with controlled temperature and gas conditions. Discover how microplate readers with gas mixers enhance cell viability in live cell-based assays.

• Spray Dried Dispersions In Controlled Release Formulations

  Integrating spray dried dispersions with CR strategies addresses poor drug solubility and the need for tailored release kinetics. Explore considerations to ensure stability and sustained supersaturation.

• Safety Of Injectables: Ensuring Purity Via Endotoxin Testing

  7/28/2026

  Advance pharmaceutical quality and sustainability by adopting recombinant factor C testing for reliable, animal-free endotoxin detection.

• From Sequence To Scale In Seven Months

  9/26/2026

  Accelerate recombinant protein development from sequence to scale while maintaining stable expression, manufacturing efficiency, and critical quality attributes.

• Screening For Amorphous Drug Substance

  5/6/2026

  Incorporate amorphous form screening early in development to unlock solubility advantages, improve bioavailability, and accelerate your path to market.

• Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)

  6/15/2026

  ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.

• Complementary Methodologies For Analysis Of NISTmAb Impurities

  2/27/2026

  Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.